Protein Kinase B Localization and Activation Differentially Affect S6 Kinase 1 Activity and Eukaryotic Translation Initiation Factor 4E-binding Protein 1 Phosphorylation
Overview
Affiliations
Recent studies indicate that phosphatidylinositide-3OH kinase (PI3K)-induced S6 kinase (S6K1) activation is mediated by protein kinase B (PKB). Support for this hypothesis has largely relied on results obtained with highly active, constitutively membrane-localized alleles of wild-type PKB, whose activity is independent of PI3K. Here we set out to examine the importance of PKB signaling in S6K1 activation. In parallel, glycogen synthase kinase 3beta (GSK-3beta) inactivation and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation were monitored as markers of the rapamycin-insensitive and -sensitive branches of the PI3K signaling pathway, respectively. The results demonstrate that two activated PKBalpha mutants, whose basal activity is equivalent to that of insulin-induced wild-type PKB, inhibit GSK-3beta to the same extent as a highly active, constitutively membrane-targeted wild-type PKB allele. However, of these two mutants, only the constitutively membrane-targeted allele of PKB induces S6K1 activation. Furthermore, an interfering mutant of PKB, which blocks insulin-induced PKB activation and GSK-3beta inactivation, has no effect on S6K1 activation. Surprisingly, all the activated PKB mutants, regardless of constitutive membrane localization, induce 4E-BP1 phosphorylation and the interfering PKB mutant blocks insulin-induced 4E-BP1 phosphorylation. The results demonstrate that PKB mediates S6K1 activation only as a function of constitutive membrane localization, whereas the activation of PKB appears both necessary and sufficient to induce 4E-BP1 phosphorylation independently of its intracellular location.
MET receptor serves as a promising target in melanoma brain metastases.
Redmer T, Schumann E, Peters K, Weidemeier M, Nowak S, Schroeder H Acta Neuropathol. 2024; 147(1):44.
PMID: 38386085 PMC: 10884227. DOI: 10.1007/s00401-024-02694-1.
Lee C, Cremona M, Farrelly A, Workman J, Kennedy S, Aslam R Cancer Biol Ther. 2023; 24(1):2223388.
PMID: 37326340 PMC: 10281467. DOI: 10.1080/15384047.2023.2223388.
Ganesh S, Subathra Devi C Mol Biol Rep. 2023; 50(4):3815-3833.
PMID: 36696023 PMC: 9875782. DOI: 10.1007/s11033-023-08283-x.
Delivery of Active AKT1 to Human Cells.
Siddika T, Balasuriya N, Frederick M, Rozik P, Heinemann I, ODonoghue P Cells. 2022; 11(23).
PMID: 36497091 PMC: 9738475. DOI: 10.3390/cells11233834.
Mori Y, Takeuchi A, Miyagawa K, Yoda H, Soda H, Nabeya Y FEBS Open Bio. 2021; 11(5):1382-1394.
PMID: 33720534 PMC: 8091590. DOI: 10.1002/2211-5463.13145.